Efficacy and safety of canaglifozin as add-on therapy to metformin in type 2 diabetes

Clinical Diabetes

Volumn 32, Issue 2, 2014, Pages 81-86

  Battise, Dawn M ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SITAGLIPTIN;

ADD ON THERAPY; ADULT; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GENITAL MYCOTIC INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POLYURIA; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 84898900618     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.32.2.81     Document Type: Note

References (13)

1. Kitabchi AE, Medaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D: Actos Now for the Prevention of Diabetes (ACT NOW) study. BMC Endocr Disord 9:17, 2009 (doi: 10.1186/1472-6823-9-7)
2. Bagust A, Beale S: Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 96:281-288, 2003
3. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, For the ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-1379, 2012
5. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarder ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH: American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 19 (Suppl. 2):1-48, 2013
6. Abdul-Ghani MA, Norton L, DeFronzo RA: Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32:515-531, 2011
7. Neumiller JJ, White JR Jr, Campbell RK: Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70:377-385, 2010
8. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu Min, Yee J, Kawaguchi M, Canovatchel W, Meininger G: Canaglifozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfo-nylurea: a 52-week randomized trial. Diabetes Care 36:2508-2515, 2013
9. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11: 1163-1172, 2009
10. Bolinder J, Ljunggren O, Kullberg, J Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S: Effects of dapaglifozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020 -1031, 2012
11. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G: Effcacy and safety of canaglifozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463-473, 2013
12. Rosebraugh CJ: U.S. Food and Drug Administration: Invokana NDA approval. Available from http://www.accessdata.fda. gov/drugsatfda_docs/appletter/2013/204042O rig1s000ltr.pdf. Accessed 2 February 2014
13. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D: Rationale, design, and baseline characteristics of the Canaglifozin Cardiovascular Assessment Study (CANVAS): a randomized placebo-controlled trial. Am Heart J 166:217-223, 2013